Aignostics

What Aignostics does

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York. Their mission is to transform drug development and improve patient outcomes with AI that delivers novel insights for precision medicine.

Products

• Pathology Foundation ModelsLeverage foundation models to generate embeddings for model training or develop custom downstream applications for pathology workflows.
• Aignostics Atlas Product SeriesA series of products for precision medicine, including Atlas H&E-TME.
• Atlas H&E-TMEA comprehensive tumor microenvironment profiling application built using the leading foundation model, Atlas 2. It provides detailed insights about the tumor microenvironment in H&E-stained whole slide images.
• Atlas 2A leading foundation model co-developed by Aignostics and Mayo Clinic, powering Atlas H&E-TME.
• Aignostics-Bayer Target ID PlatformA jointly developed platform that integrates proteomics, transcriptomics, epigenomics, and imaging data into a single multimodal AI model for target identification.

Key capabilities

• Proprietary access to multimodal clinical datasets
• Industry-leading AI technologies
• Rigorous science
• Pathology Foundation Models for embeddings and custom applications
• Comprehensive tumor microenvironment profiling
• Advanced machine learning capabilities
• Multimodal AI model integration (proteomics, transcriptomics, epigenomics, imaging data)

Use cases

• Drug discovery
• Translational research
• Clinical trials
• CDx development
• Target & Biomarker Discovery
• Complex image and data analysis
• Measuring complex biomarkers
• Predicting expression patterns across data modalities
• Refining proof-of-concept models into validated clinical tools
• Tumor microenvironment analysis
• Pancreatic Cancer Research

AI approach

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for precision medicine. They leverage foundation models for pathology workflows and advanced analytic techniques for drug discovery, translational research, clinical trials, and CDx development.

Tech named: foundation models, deep learning, AI, machine learning

Industries served

• Biopharma
• Healthcare
• Academic Research

What it says sets it apart

• Proprietary access to multimodal clinical datasets from over 30M patients at leading university hospitals and laboratories
• Deep biomedical expertise from a team of data scientists, machine learning engineers, pathologists, and biologists
• Advanced machine learning capabilities, including industry-leading foundation models and advanced analytic techniques
• Cutting-edge collaborations with academic partners in the EU and US
• Spin-off from Charité Berlin, one of Europe’s largest and most esteemed university hospitals
• Interdisciplinary team with deep functional competency
• Focus on precision medicine
• Rigorous development of products and services

Funding rounds we track

From the AI funding tracker — rounds as reported by the linked publications.